iBio, Inc. - 8-K Filing
iBio reported Q3 fiscal year 2026 financial results with no revenue for the three months ended March 31, 2026. R&D expenses increased to $3.3 million from $1.9 million in the same period last year due to higher spending on consultants and personnel costs related to its IBIO-600 and IBIO-610 programs. General and administrative expenses rose to $5.1 million, primarily driven by a $2.5 million impairment of an intangible asset. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $IBIO